Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
46 papers
Researchers are actively testing psilocybin (the active part of “magic mushrooms”) as a possible treatment for several mental health problems. Early clinical trials—usually done under medical supervision with therapy before and after the drug session—have found quick improvements in some people with major depression, anxiety linked to serious illness, and other hard-to-treat conditions (but the studies are still small). (15135,15063,15056) Scientists propose several ways psilocybin might help, such as changing how brain networks communicate, boosting the brain’s ability to form new connections, and lowering brain inflammation. However, the exact reasons are not settled. Safety in careful clinical settings looks acceptable so far, but harms may be underreported, and unsupervised use can carry real risks. More and larger trials are needed, and many groups (for example people of color) were not well represented in early studies. (15132,15050,15135,15061,15095,15056)
Compass Pathways reported early results from its first Phase 3 trial of synthetic psilocybin (COMP360) for treatment‑resistant depression. In 258 patients, the 25 mg dose showed a statistically significant improvement versus placebo on the MADRS depression scale at week 6 (a 3.6‑point difference, p < 0.001). The Data and Safety…
Researchers gave different psychedelic drugs to mice and found the drugs could reopen a window of brain plasticity used for learning social rewards. This reopened window went along with changes in a social hormone system in a key reward area of the brain and with changes in genes that control…
This paper describes psychedelic-assisted psychotherapy, which means giving drugs like ketamine, MDMA, psilocybin, LSD or ibogaine together with guided therapy. The authors say this approach has shown promising safety and benefits so far, even for people who did not get better with usual treatments. They also argue that these therapies…
This review explains how the mushroom drugs psilocybin and psilocin are broken down in the body. Psilocybin is mainly a pro-drug that enzymes convert into the active compound psilocin. Psilocin is then further changed, and the main substance found in urine is psilocin-O-glucuronide, which matters for clinical and forensic testing.…
Microdosing means taking a very small, sub‑hallucinogenic amount of a psychedelic drug. Research so far is limited and mixed: some large observational studies report small-to-medium mood gains, but at least one randomized trial found no objective benefit. There is no standard definition of microdosing, potency and legality vary, and long‑term…
This paper reviews the recent comeback of psychedelic research and points out that much of that work borrows from indigenous healing traditions. The authors say Indigenous people, ethnic and racial minorities, women, and other marginalized groups are often left out of research and the mainstream story about psychedelic medicine. The…
Researchers collected and read 15 studies where patients described their own experiences with psychedelic treatments for mental disorders. These studies looked at about 180 patient accounts across different drugs and different illnesses. Even though the drugs and treatment settings were very different, many patients described similar helpful processes, such as…
Researchers around the world have started clinical studies again to see if psychedelic drugs can help treat serious mental health problems. This work picks up after research that stopped around the 1950s. Scientists are running controlled studies to test whether these substances can safely reduce problems like depression, anxiety, addiction…
Researchers reviewed studies of drugs that act on serotonin (so-called serotonergic psychedelics) and MDMA. They found that harms and bad reactions are not clearly defined in these studies and are probably reported less often than they actually happen. Some intense or frightening experiences during treatment might help people heal, but…
Recent, early-phase trials suggest psychedelics—especially psilocybin—may help treat several mental and substance use disorders. The psychedelic experience can include loss of self-importance, feelings of unity or connection, ineffable insights, and encounters with ‘deep’ reality or God, and it can change a person’s personality and worldview. The authors argue these unusual…
This systematic review searched for clinical trials of psilocybin for substance use problems up to September 2, 2022. The authors found four trials with 151 patients that tested psilocybin combined with psychotherapy for alcohol or tobacco use. These small trials, including one randomized placebo-controlled trial, reported reductions in heavy drinking…
This 2021 review of human studies found that classic psychedelics (for example psilocybin, LSD, ayahuasca) tend to reduce performance on standard memory tests in a dose-dependent way: low doses usually showed no impairment and higher doses caused more impairment. At the same time, these drugs often made autobiographical memories feel…
